Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study checks if skin prep really kills germs

NCT ID NCT01366417

Knowledge-focused Sponsor: C. R. Bard Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested how well a skin disinfectant called ChloraPrep kills bacteria on the skin before injections. 25 healthy adults had the disinfectant applied, and researchers measured bacteria levels after 30 seconds and 10 minutes. The goal was to see if it works better than a standard alcohol pad.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ChloraPrep (chlorhexidine gluconate and isopropyl alcohol)
What this could lead to
If successful, this could confirm that ChloraPrep effectively reduces bacteria on the skin before injections, supporting its use in clinical settings.
What could go wrong
This is a small, early-phase study with only 25 healthy adults, so results may not apply to all patients or settings. It measures bacteria counts, not infection rates.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

25 people

The number who actually took part.

Start date

May 2011

Finished

Jun 2011

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * in good general health * have skin within 6 inches of the test sites that is free of tattoos, dermatoses, abrasions, cuts, lesions or other skin disorders. Exclusion Criteria: \- topical or systemic antimicrobial exposure within 14 days prior to the Screen Visit

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Antimicrobial effectiveness are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Antimicrobial effectiveness

Contacts and locations

Locations

  • Microbiotest

    Sterling, Virginia, 20164, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.